<Suppliers Price>

PPQ 102

Names

[ CAS No. ]:
931706-15-9

[ Name ]:
PPQ 102

[Synonym ]:
7,9-Dimethyl-6-(5-methyl-2-furyl)-11-phenyl-6,7-dihydropyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9H)-dione
Pyrimido[4',5':3,4]pyrrolo[1,2-a]quinoxaline-8,10(5H,9H)-dione, 6,7-dihydro-7,9-dimethyl-6-(5-methyl-2-furanyl)-11-phenyl-
7.9-Dimethylxanthin
7,9-dimethoxy-5H-pyrido<3,2-c>azepine
7,9-dimethylxanthine
7,9-dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purinium betaine
7,9-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydro-purinium-betain
7,9-dimethoxy-5H-pyrido<3,2-c>-azephine
3,9-dimethylxanthine
PPQ-102

Biological Activity

[Description]:

PPQ-102 is a potent CFTR inhibitor which can completely inhibited CFTR chloride current with IC50 of ~90 nM. IC50 value: 90 nM [1]Target: CFTRin vitro: The most potent compound, 7,9-dimethyl-11-phenyl-6-(5-methylfuran-2-yl)-5,6-dihydro-pyrimido[4',5'-3,4]pyrrolo[1,2-a]quinoxaline-8,10-(7H,9H)-dione, PPQ-102, completely inhibited CFTR chloride current with IC(50) approximately 90 nM. The PPQs, unlike prior CFTR inhibitors, are uncharged at physiological pH, and therefore not subject to membrane potential-dependent cellular partitioning or block efficiency. Patch-clamp analysis confirmed voltage-independent CFTR inhibition by PPQ-102 and showed stabilization of the channel closed state [1]. The three gpSlc26 anion transporters exhibited distinct pharmacological profiles of (36)Cl(-) influx, including partial sensitivity to CFTR inhibitors Inh-172 and GlyH101, but only Slc26a11 was inhibited by PPQ-102 [2]. Airway epithelial NCI-H292 cells and primary cultures of noncystic fibrosis human airway epithelial cells were treated with cystic fibrosis transmembrane conductance regulator (CFTR) inhibitors (CFTR-inh(172) or PPQ-102) or transfected with a CFTR small interfering (si)RNA with or without a selective epidermal growth factor receptor tyrosine kinase inhibitor [3].in vivo: PPQ-102 prevented cyst expansion and reduced the size of preformed cysts in a neonatal kidney organ culture model of polycystic kidney disease. PPQ-102 is the most potent CFTR inhibitor identified to date [1].

[Related Catalog]:

Signaling Pathways >> Membrane Transporter/Ion Channel >> CFTR
Research Areas >> Others

[References]

[1]. Tradtrantip L, et al. Nanomolar potency pyrimido-pyrrolo-quinoxalinedione CFTR inhibitor reduces cyst size in a polycystic kidney disease model. J Med Chem. 2009 Oct 22;52(20):6447-55.

[2]. Stewart AK, et al. SLC26 anion exchangers of guinea pig pancreatic duct: molecular cloning and functional characterization. Am J Physiol Cell Physiol. 2011 Aug;301(2):C289-303.

[3]. Martin C, et al. CFTR dysfunction induces vascular endothelial growth factor synthesis in airway epithelium. Eur Respir J. 2013 Dec;42(6):1553-62.


[Related Small Molecules]

Lumacaftor (VX-809) | CFTR(inh)-172 | Tezacaftor(VX-661) | GlyH 101 | GLPG1837 | BPO-27 racemate | IOWH032 | KM 11060

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
648.7±65.0 °C at 760 mmHg

[ Molecular Formula ]:
C26H22N4O3

[ Molecular Weight ]:
438.478

[ Flash Point ]:
346.1±34.3 °C

[ Exact Mass ]:
438.169189

[ PSA ]:
74.10000

[ LogP ]:
3.48

[ Appearance of Characters ]:
white solid

[ Vapour Pressure ]:
0.0±1.9 mmHg at 25°C

[ Index of Refraction ]:
1.720

[ Storage condition ]:
-20℃

Synthetic Route

Precursor & DownStream


Related Compounds